Actuate Therapeutics’ Lock-Up Period To End on February 10th (NASDAQ:ACTU)

Actuate Therapeutics’ (NASDAQ:ACTU) lock-up period will end on Monday, February 10th. Actuate Therapeutics had issued 2,800,000 shares in its initial public offering on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Actuate Therapeutics Price Performance

NASDAQ ACTU opened at $8.82 on Friday. The company has a fifty day simple moving average of $8.48. Actuate Therapeutics has a 12-month low of $5.51 and a 12-month high of $11.73.

Institutional Trading of Actuate Therapeutics

Several hedge funds have recently bought and sold shares of the business. Freestone Capital Holdings LLC purchased a new position in Actuate Therapeutics during the 4th quarter worth $80,000. Sigma Planning Corp bought a new stake in shares of Actuate Therapeutics during the 4th quarter worth $128,000. Northwestern University bought a new stake in shares of Actuate Therapeutics during the 3rd quarter worth $207,000. Finally, KG&L Capital Management LLC bought a new stake in shares of Actuate Therapeutics during the 3rd quarter worth $89,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.